BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Monteleone G, Di Sabatino A, Ardizzone S, Pallone F, Usiskin K, Zhan X, Rossiter G, Neurath MF. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn’s disease. Aliment Pharmacol Ther. 2016;43:717-724. [PMID: 26766141 DOI: 10.1111/apt.13526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Arrico L, Stolfi C, Marafini I, Monteleone G, Demartis S, Bellinvia S, Viti F, McNulty M, Cabani I, Falezza A, Di Bari L. Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment. Nucleic Acid Ther 2022. [PMID: 35263186 DOI: 10.1089/nat.2021.0089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. BioDrugs 2021;35:325-36. [PMID: 33871807 DOI: 10.1007/s40259-021-00482-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen X, Berin MC, Gillespie VL, Sampson HA, Dunkin D. Treatment of Intestinal Inflammation With Epicutaneous Immunotherapy Requires TGF-β and IL-10 but Not Foxp3+ Tregs. Front Immunol 2021;12:637630. [PMID: 33717186 DOI: 10.3389/fimmu.2021.637630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Batura V, Muise AM. Very early onset IBD: novel genetic aetiologies. Curr Opin Allergy Clin Immunol 2018;18:470-80. [PMID: 30299396 DOI: 10.1097/ACI.0000000000000486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
5 Giuffrida P, Cococcia S, Delliponti M, Lenti MV, Di Sabatino A. Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease. Cells 2019;8:E397. [PMID: 31052214 DOI: 10.3390/cells8050397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
6 Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. J Crohns Colitis. 2018;12:S641-S652. [PMID: 30137309 DOI: 10.1093/ecco-jcc/jjx145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
7 de Souza HSP. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opin Gastroenterol. 2017;33:222-229. [PMID: 28402995 DOI: 10.1097/mog.0000000000000364] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
8 White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:1610-1622. [PMID: 29672874 DOI: 10.1111/apt.14669] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
9 Labetoulle R, Paul S, Roblin X. Filgotinib for the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:295-300. [DOI: 10.1080/13543784.2018.1442433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
10 Giuffrida P, Corazza GR, Di Sabatino A. Old and New Lymphocyte Players in Inflammatory Bowel Disease. Dig Dis Sci 2018;63:277-88. [DOI: 10.1007/s10620-017-4892-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
11 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
12 Curciarello R, Docena GH, MacDonald TT. The Role of Cytokines in the Fibrotic Responses in Crohn's Disease. Front Med (Lausanne) 2017;4:126. [PMID: 28824915 DOI: 10.3389/fmed.2017.00126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
13 Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017;66:1049-59. [PMID: 28209624 DOI: 10.1136/gutjnl-2016-312735] [Cited by in Crossref: 204] [Cited by in F6Publishing: 171] [Article Influence: 40.8] [Reference Citation Analysis]
14 Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol 2017;52:777-87. [PMID: 28534191 DOI: 10.1007/s00535-017-1350-1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 23.4] [Reference Citation Analysis]
15 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
16 Lee HJ, Park JM, Hahm KB. [Role of Inhibitory Transforming Growth Factor-β Signal Smad7 in Helicobacter pylori-associated Gastric Damage]. Korean J Gastroenterol 2016;68:186-94. [PMID: 27780942 DOI: 10.4166/kjg.2016.68.4.186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Gabbani T, Deiana S, Marocchi M, Annese V. Genetic risk variants as therapeutic targets for Crohn's disease. Expert Opin Ther Targets 2017;21:381-90. [PMID: 28281904 DOI: 10.1080/14728222.2017.1296431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [PMID: 27856614 DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 15.4] [Reference Citation Analysis]
19 Huang Y. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics. Mol Ther Nucleic Acids 2017;6:116-32. [PMID: 28325278 DOI: 10.1016/j.omtn.2016.12.003] [Cited by in Crossref: 148] [Cited by in F6Publishing: 138] [Article Influence: 24.7] [Reference Citation Analysis]
20 Coskun M, Vermeire S, Nielsen OH. Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol Sci. 2017;38:127-142. [PMID: 27916280 DOI: 10.1016/j.tips.2016.10.014] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 13.8] [Reference Citation Analysis]
21 Kirchgesner J, Sokol H. Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution? Aliment Pharmacol Ther 2016;43:838-9. [PMID: 26932411 DOI: 10.1111/apt.13563] [Reference Citation Analysis]
22 Szűcs D, Béres NJ, Rokonay R, Boros K, Borka K, Kiss Z, Arató A, Szabó AJ, Vannay &, Sziksz E, Bereczki C, Veres G. Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease. World J Gastroenterol 2016; 22(26): 6027-6035 [PMID: 27468194 DOI: 10.3748/wjg.v22.i26.6027] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
23 Raad MA, Chams NH, Sharara AI. New and Evolving Immunotherapy in Inflammatory Bowel Disease. Inflamm Intest Dis. 2016;1:85-95. [PMID: 29922662 DOI: 10.1159/000445986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]